Table 4.
Selected studies on high-intensity ultrasound
| Study | Number of patients | Approach | Follow up | Overal survival, median (months) | Progression free time (months) | Regression/ stable disease rate (%) | Progression rate (%) | Recurrence rate (%) | Complications rate (%) | Mortality rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Marinova et al. (2018) [93] | 50 | Percutaneous, US-guided | 3 years | 16.2 | 6.8 | 972 regression of tumor volume | NA | 44 (10 local, 12 distant) | 64 | 0 |
| Sung et al. (2011) [94] | 46 | Percutaneous, US-guided | NA | 12.4 | NA | NA | NA | NA | 67.3 | 0 |
| Xiong et al. (2009) [95] | 89 | Percutaneous, US-guided | 36 months | 8.6 (stage II-IV) |
NA | 14.5 partial response 57.3 stable (no change) |
28.1 | NA | 11.2 | 0 |
| Zhao et al. (2017) [96] | 38 | Percutaneous, US-guided | NA | 10.3 (low power cumulative HIFU) 6 (traditional HIFU) |
NA | NA | NA | NA | NA | 0 |
| Yi et al. (2018) [24] | 87 | Percutaneous, US-guided | 16 | 12.2 | NA | 8 complete response 28.9 partial response 41.3 stable disease |
21.8 | NA | 28.7 | 0 |